Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 6/2014

01-08-2014 | Research Paper

Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins

Authors: L. Carduner, J. Leroy-Dudal, C. R. Picot, O. Gallet, F. Carreiras, S. Kellouche

Published in: Clinical & Experimental Metastasis | Issue 6/2014

Login to get access

Abstract

At least one-third of patients with epithelial ovarian cancer (OC) present ascites at diagnosis and almost all have ascites at recurrence. The presence of ascites, which acts as a dynamic reservoir of active molecules and cellular components, correlates with the OC peritoneal metastasis and is associated with poor prognosis. Since epithelial-mesenchymal transition (EMT) is involved in different phases of OC progression, we have investigated the effect of the unique ascitic tumor microenvironment on the EMT status and the behavior of OC cells. The exposure of three OC cell lines to ascites leads to changes in cellular morphologies. Within ascites, OC cells harboring an initial intermediate epithelial phenotype are characterized by marked dislocation of epithelial markers (E-cadherin, ZO-1 staining) while OC cells initially harboring an intermediate mesenchymal phenotype strengthen their mesenchymal markers (N-cadherin, vimentin). Ascites differentially triggers a dissemination phenotype related to the initial cell features by either allowing the proliferation and the formation of spheroids and the extension of colonies for cells that present an initial epithelial intermediate phenotype, or favoring the migration of cells with a mesenchymal intermediate phenotype. In an ascitic microenvironment, a redeployment of αv integrins into cells was observed and the ascites-induced accentuation of the two different invasive phenotypes (i.e. spheroids formation or migration) was shown to involve αv integrins. Thus, ascites induces a shift toward an unstable intermediate state of the epithelial-mesenchymal spectrum and confers a more aggressive cell behavior that takes on a different pathway based on the initial epithelial-mesenchymal cell features.
Literature
1.
Kipps E, Tan DSP, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13:273–282PubMedCrossRef
2.
Heyman L, Kellouche S, Fernandes J et al (2008) Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. Tumour Biol 29:231–244PubMedCrossRef
3.
4.
Shield K, Ackland ML, Ahmed N et al (2009) Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 113:143–148PubMedCrossRef
5.
Kenny HA, Kaur S, Coussens LM et al (2008) The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 118:1367–1379PubMedCentralPubMedCrossRef
6.
7.
Ayhan A, Gultekin M, Taskiran C et al (2007) Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer 17:68–75PubMedCrossRef
8.
Tan DSP, Agarwal R, Kaye SB (2006) Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 7:925–934PubMedCrossRef
9.
Puiffe M-L, Le Page C, Filali-Mouhim A et al (2007) Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9:820–829PubMedCentralPubMedCrossRef
10.
Lane D, Goncharenko-Khaider N, Rancourt C et al (2010) Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 29:3519–3531PubMedCrossRef
11.
Carduner L, Agniel R, Kellouche S et al (2013) Ovarian cancer ascites-derived vitronectin and fibronectin: combined purification, molecular features and effects on cell response. Biochim Biophys Acta BBA 1830(10):4885–4897CrossRef
12.
Cruet-Hennequart S, Maubant S, Luis J et al (2003) alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 22:1688–1702PubMedCrossRef
13.
Reuning U (2011) Integrin αvβ3 promotes vitronectin gene expression in human ovarian cancer cells by implicating rel transcription factors. J Cell Biochem 112:1909–1919PubMedCrossRef
14.
Leroy-Dudal J, Demeilliers C, Gallet O et al (2005) Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Int J Cancer 114:531–543PubMed
15.
Carreiras F, Rigot V, Cruet S et al (1999) Migration properties of the human ovarian adenocarcinoma cell line IGROV1: importance of alpha(v)beta3 integrins and vitronectin. Int J Cancer 80:285–294PubMed
16.
Landen CN, Kim T-J, Lin YG et al (2008) Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10:1259–1267PubMedCentralPubMed
17.
Davidson B, Goldberg I, Gotlieb WH et al (2003) Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway? Cancer Metastasis Rev 22:103–115PubMedCrossRef
18.
Ahmed N, Thompson EW, Quinn MA (2007) Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol 213:581–588PubMedCrossRef
19.
Ahmed N, Abubaker K, Findlay J et al (2010) Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 10:268–278PubMedCrossRef
20.
Thiery JP, Acloque H, Huang RYJ et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890PubMedCrossRef
21.
Huang RY-J, Wong MK, Tan TZ et al (2013) An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis 4:e915PubMedCentralPubMedCrossRef
22.
23.
24.
Moreno-Bueno G, Peinado H, Molina P et al (2009) The morphological and molecular features of the epithelial-to-mesenchymal transition. Nat Protoc 4:1591–1613PubMedCrossRef
25.
26.
Shaw TJ, Senterman MK, Dawson K et al (2004) Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10:1032–1042PubMedCrossRef
27.
Bénard J, Da Silva J, De Blois MC et al (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 45:4970–4979PubMed
28.
Hamilton TC, Young RC, McKoy WM et al (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43:5379–5389PubMed
29.
Ward BG, Wallace K, Shepherd JH et al (1987) Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res 47:2662–2667PubMed
30.
Staack A, Badendieck S, Schnorr D et al (2006) Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol 6:19PubMedCentralPubMedCrossRef
31.
32.
Villedieu M, Briand M, Duval M et al (2007) Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression. Gynecol Oncol 105:373–384PubMedCrossRef
33.
Ahmed N, Riley C, Oliva K et al (2005) Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer 92:1475–1485PubMedCentralPubMedCrossRef
34.
Lee S, Yang Y, Fishman D et al (2013) Epithelial-mesenchymal transition enhances nanoscale actin filament dynamics of ovarian cancer cells. J Phys Chem B 117:9233–9240PubMedCentralPubMed
35.
36.
Auersperg N, Wong AS, Choi KC et al (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22:255–288PubMed
37.
Hudson LG, Zeineldin R, Stack MS (2008) Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 25:643–655PubMedCentralPubMedCrossRef
38.
Quattrocchi L, Green AR, Martin S et al (2011) The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. Virchows Arch 459:21–29PubMedCrossRef
39.
Sivertsen S, Berner A, Michael CW et al (2006) Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol 50:603–607PubMedCrossRef
40.
Comamala M, Pinard M, Thériault C et al (2011) Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 104:989–999PubMedCentralPubMedCrossRef
41.
Ponnusamy MP, Lakshmanan I, Jain M et al (2010) MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene 29:5741–5754PubMedCentralPubMedCrossRef
42.
Latifi A, Luwor RB, Bilandzic M et al (2012) Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS ONE 7:e46858PubMedCentralPubMedCrossRef
43.
Wintzell M, Hjerpe E, Åvall Lundqvist E, Shoshan M (2012) Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer 12:359PubMedCentralPubMedCrossRef
44.
Thibault B, Castells M, Delord JP, Couderc B (2013) Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev. doi:10.​1007/​s10555-013-9456-2 PubMed
45.
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):09–322CrossRef
46.
Carduner L, Picot CR, Leroy-Dudal J et al (2013) Cell cycle arrest or survival signaling through αv integrins and activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. Exp Cell Res 320(2):329–342PubMedCrossRef
47.
Pease JC, Brewer M, Tirnauer JS (2012) Spontaneous spheroid budding from monolayers: a potential contribution to ovarian cancer dissemination. Biol Open 1:622–628PubMedCentralPubMedCrossRef
48.
Makhija S, Sabbatini P, Barakat RR (1999) Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. Curr Opin Obstet Gynecol 11:23–27PubMedCrossRef
49.
Veatch AL, Carson LF, Ramakrishnan S (1994) Differential expression of the cell–cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer 58:393–399PubMed
50.
Rosanò L, Spinella F, Di Castro V et al (2005) Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 65:11649–11657PubMedCrossRef
51.
Kellouche S, Fernandes J, Leroy-Dudal J et al (2010) Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin. Tumour Biol 31:129–139PubMedCrossRef
52.
Uhm JH, Dooley NP, Kyritsis AP et al (1999) Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 5:1587–1594PubMed
53.
Xing H, Weng D, Chen G et al (2008) Activation of fibronectin/PI-3 K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 261:108–119PubMedCrossRef
54.
Matte I, Lane D, Laplante C et al (2012) Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2:566–580PubMedCentralPubMed
55.
Valdembri D, Serini G (2012) Regulation of adhesion site dynamics by integrin traffic. Curr Opin Cell Biol 24:582–591PubMedCrossRef
Metadata
Title
Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins
Authors
L. Carduner
J. Leroy-Dudal
C. R. Picot
O. Gallet
F. Carreiras
S. Kellouche
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 6/2014
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-014-9658-1

Other articles of this Issue 6/2014

Clinical & Experimental Metastasis 6/2014 Go to the issue

Research Paper

COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib

Research Paper

Galectin-3 expressed on different lung compartments promotes organ specific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells

Research Paper

Metadherin expression and lung relapse in patients with colorectal carcinoma

Review

Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs

Research Paper

High expression of S100A4 and endoglin is associated with metastatic disease in head and neck squamous cell carcinoma

Research Paper

Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits